Main Contractor/CL3 Laboratory: Validation Centre – Full and complete service for the duration of the project life cycle OPS – 0067
The procurement contact named on the official notice.
Medicines Discovery Catapult (MDC) is a national facility for collaborative R&D exploring and developing new approaches to the discovery and proof of well targeted medicines, diagnostics and biomarkers.
Funded by Innovate UK, an agency of the UK government, MDC are an independent not-for-profit company bringing together a fragmented UK sector of industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high value products.
By sharing problems, rare expertise and assets we support the growth of this new community through a time of radical business and national change.
Capitalising on the success of the Lighthouse Lab to create a new CL3 facility for innovative diagnostics, biomarkers and complex medicines and develop the UK’s onshore diagnostic capability and capacity and the associated supply chain.
The project will create a national facility for testing and validation of new diagnostics, biomarkers and innovative therapeutics for disease.
The Validation Centre of Excellence will enable innovators to set up new companies with confidence, driving regional growth in high-value jobs and a sector of urgent national and global need.
The Centre will build on the Lighthouse brand, creating a hub for new diagnostic and therapeutic validation.
Main Contractor: Further information can be found at https://procontract.due-north.com/RFx/RFxSummary?rfxId=d9ecb11e-cfbe-eb11-810c-005056b64545&projectId=833bb7e1-cbbe-eb11-810c-005056b64545
What the supplier must deliver
By sharing problems, rare expertise and assets
By sharing problems, rare expertise and assets we support the growth of this new community through a time of radical business and national change.
Capitalising on the success of the Lighthouse
Capitalising on the success of the Lighthouse Lab to create a new CL3 facility for innovative diagnostics, biomarkers and complex medicines and develop the UK’s onshore diagnostic capability and capacity and the associated supply chain.
Derived from the notice text — always confirm against the original documents.
Make the case to bid
Reveal who to approach at Medicines Discovery Catapult, and generate a go-to-market strategy from their news, accounts and people.
- OCID
- ocds-h6vhtk-02b60c
- Stage
- tender · Open
- Source
- Find a Tender
- Buyer ref
- 011930-2021
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
Top suppliers & buyers in Construction
Assembling the market network…
Medicines Discovery Catapult’s tender network
Assembling the network…